Pharma & Bio
Technology
Hanmi Signs $2.3B Obesity Drug Deal With Roche [K-Bio Pulse]
On Aug. 24, South Korea’s pharmaceutical and life sciences sectors both posted strong gains.The pharmaceutical sector rose 3.3% from the previous session. Among 161 stocks, 116 advanced, 14 remained u…
Lifestyle
Pharmaceutical Stocks Soar on HanmiPharm’s 3.5 Trillion Won Windfall… Orum and AbClon Inc. Also Surge [Bio Spotlight]
On the 24th, the pharmaceutical and life sciences sectors both posted strong gains on the domestic stock market.On that day, the pharmaceutical sector rose 3.3% compared to the previous trading day. O…
Lifestyle
Kim Jae-jin, CEO of IoFlow: “We’ve Filed an Appeal Against the Delisting Decision… and Secured a Commitment for the Necessary Investment”
IoFlow is filing an appeal against the delisting decision made by the Korea Exchange’s Corporate Review Committee (CRC). IoFlow maintains that if the appeal is accepted, it will be able to resolve a s…
Lifestyle
JETEMA Co.,Ltd.’s 552 billion won Botox jackpot within reach… “440 billion won is from committed orders”
With JETEMA Co.,Ltd.(216080)having completed its application for marketing authorization in China for the botulinum toxin “JTM201,” the timing for revenue recognition from a supply contract worth appr…
Technology
Welt to Launch IPO Next Year... CEO Kang Seong-ji: “In the Face of the LLM Offensive, the Answer Lies in Patient Data; We Will Redefine the Market with ‘Clinical Smart’”
“We are moving from an era of manufacturing products to an era of creating intelligence. While global Big Tech companies, including Google, are intensifying their push into large language models (LLMs…
Technology
Global Oral GLP-1 Competition, Expansion into Heart Failure… Can Ildong and Hanmi Overcome Their Weaknesses as Latecomers?
(Graphic: Generative AI)
AstraZeneca is expanding the development scope of “elecoglipron,” an oral glucagon-like peptide-1 (GLP-1) class obesity treatment, from obesity and diabetes to heart failu…
Technology
NeoImmuneTech Hits Limit-Up for Second Day on U.S. Biotech Deal [K-Bio Pulse]
NeoImmuneTech, a South Korean developer of immuno-oncology drugs, hit its daily upper trading limit on Friday for the second consecutive session, following a licensing deal with a U.S. biotechnology c…
Technology
NeoImmuneTech, Inc. Rises for Second Consecutive Day… Advance Payment Secures Stake in U.S. Biotech Firm [Bio Spotlight]
On the 21st, the stock price of NeoImmuneTech, Inc.(950220), a developer of immuno-oncology drugs, hit the daily price limit, marking its second consecutive day at the limit following the previous tra…
Lifestyle
KMPHARMACEUTICAL Co.,Ltd. Gains Momentum from Global Expansion… Set to Surpass 20 Billion Won in Annual Revenue
Life care specialist KMPHARMACEUTICAL Co.,Ltd.(225430)has emerged from a prolonged period of stagnant performance and is now on a path of substantial revenue growth. This is the result of tangible out…
Technology
AlpBio Nears Full Capacity at Dietary Supplement Plant… Will Benefits from Drug Price Cuts Materialize?
A panoramic view of ALP Bio’s Mado plant. (Image courtesy of ALP Bio)
There is growing speculation that RP Bio, the leader in South Korea’s soft capsule market, may expand its production capacity …